Penn Medicine
Help | Search | Site Map | Contact   
faculty photo

Michael G.S. Shashaty, MD, MSCE

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Associate Scholar, Center for Clinical Epidemiology and Biostatistics
Director, Critical Care Outreach and Procedure Service, Hospital of the University of Pennsylvania
Rapid Response Medical Director, Hospital of the University of Pennsylvania
Department: Medicine

Contact information
5039 W Gates
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-615-5031
Education:
BS (Biology)
Georgetown University, 1997.
MD (Medicine)
Vanderbilt University School of Medicine, 2003.
MSCE (Clinical Epidemiology)
Perelman School of Medicine, University of Pennsylvania, 2010.
Post-Graduate Training
Intern, Internal Medicine, Hospital of the University of Pennsylvania, 2003-2004.
Resident, Internal Medicine, Hospital of the University of Pennsylvania, 2004-2006.
Fellow, Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, 2007-2010.
Certifications
Internal Medicine, American Board of Internal Medicine, 2006.
Pulmonary Diseases, American Board of Medical Specialties, 2010.
Critical Care Medicine, American Board of Medical Specialties, 2012.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Dr. Shashaty's career is focused on epidemiologic and translational research studies of the risks for and mechanisms of acute organ dysfunction, primarily acute kidney injury (AKI), in critical illness and populations.

Dr. Shashaty has formal training in the clinical practice of pulmonary and critical care medicine, biostatistical and epidemiologic methods, and protein, gene expression, and genomic analyses of human biospecimens. He is the principal investigator for the Lung Transplant Outcomes Group–Acute Kidney Injury (LTOG-AKI) study, a multicenter prospective cohort of lung transplant recipients (n>1800) designed to study the clinical and molecular epidemiology of post-lung transplant AKI. The primary focus of this study is to determine clinical characteristics and novel blood and urine biomarkers that are useful for AKI prediction and may provide insight into molecular mechanisms of AKI after transplantation.

Dr. Shashaty is also the principal investigator for the ongoing Penn Trauma Organ Dysfunction Study (PETROS), a cohort of critically ill trauma patients (n>1300), and a co-investigator in Penn’s Molecular Epidemiology of Severe Sepsis in the ICU (MESSI) cohort, for which he leads studies of AKI. Current areas of study in these cohorts include elucidating mechanisms underlying the association of obesity and AKI, the relevance of programmed cell necrosis in human AKI and ARDS, circulating cell-free DNA as a mechanistic contributor to AKI and ARDS, and genetic risk factors for AKI.

Description of Clinical Expertise

Dr. Shashaty is specialty-trained in internal medicine, pulmonary diseases, and critical care medicine. He is an attending physician at the Hospital of the University of Pennsylvania (HUP), with the majority of his clinical time spent in the medical intensive care unit. He also attends on and is the service lead for the Critical Care Outreach and Procedure Service (CCOPS).

Dr. Shashaty is currently the Rapid Response Medical Director at HUP. In this capacity, he works with a multidisciplinary team to provide oversight, design and conduct training, and pursue quality improvement initiatives in the areas of clinical emergencies and management of cardiac arrest. He has played a central role in adapting HUP's clinical emergencies team to the COVID-19 pandemic.

Dr. Shashaty is actively engaged in teaching fellows, house officers, medical students, and advanced practice providers through both HUP clinical services, classes at the Perelman School of Medicine, and training programs at the Penn School of Nursing.

Selected Publications

Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson BJ, Wilson FP, Townsend R, Reilly JP, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS.: Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Med Jul 2022.

Pike DP, McGuffee RM, Geerling E, Albert CJ, Hoft DF, Shashaty MGS, Meyer NJ, Pinto AK, Ford DA: Plasmalogen Loss in Sepsis and SARS-CoV-2 Infection. Frontiers in Cell and Developmental Biology 10, Jun 2022.

Mitchell OJL, Dewan M, Wolfe HA, Roberts KJ, Neefe S, Lighthall G, Sands NA, Weissman G, Ginestra J, Shashaty MGS, Schweickert WD, Abella BS: Defining Physiological Decompensation: An Expert Consensus and Retrospective Outcome Validation. Critical Care Explorations 4(4): e0677, Apr 2022 Notes: accepted for publication.

Faust HE, Oniyide O, Wang Y, Forker CM, Dunn T, Yang W, Lanken PN, Sims CA, Yehya N, Christie JD, Meyer NJ, Reilly JP, Mangalmurti NS, Shashaty MGS: Early Plasma Nuclear DNA, Mitochondrial DNA, and Nucleosome Concentrations are Associated with Acute Kidney Injury in Critically Ill Trauma Patients. Critical Care Explorations March 2022 Notes: accepted for publication.

Jones TK, Reilly JP, Anderson BJ, Miano TA, Dunn TG, Weisman AR, Agyekum R, Feng R, Ittner CAG, Shashaty MGS, Meyer NJ.: Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis. Shock 57: 41-47, Jan 2022.

Amunugama K, Jellinek MJ, Kilroy MP, Albert CJ, Rasi V, Hoft DF, Shashaty MGS, Meyer NJ, Ford DA.: Identification of novel neutrophil very long chain plasmalogen molecular species and their myeloperoxidase mediated oxidation products in human sepsis. Redox Biol 48: 102208, Dec 2021.

Wu J, Ma Z, Raman A, Beckerman P, Dhillon P, Mukhi D, Palmer M, Chen HC, Cohen CR, Dunn T, Reilly J, Meyer N, Shashaty M, Arany Z, Haskó G, Laudanski K, Hung A, Susztak K.: APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis. Immunity 54: 2632-2649, Nov 2021.

Kahn B, Apostolidis SA, Bhatt V, Greenplate AR, Kallish S, LaCava A, Lucas A, Meyer NJ, Negoianu D, Ogdie AR, Shashaty MGS, Takach PA, Zuroff L, Wherry EJ, Anesi GL.: Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination. Crit Care Explor 3: e0578, Nov 2021.

Farrell C, Miano TA, Griffiths S, Christie JD, Diamond JM, Shashaty MGS: Early post-lung transplant calcineurin inhibitor management varies widely: an international survey. Clinical Transplantation Oct 2021 Notes: Published online.

Vasquez CR, Gupta S, Miano TA, Roche M, Hsu J, Yang W, Holena DN, Reilly JP, Schrauben SJ, Leaf DE, Shashaty MGS; STOP-COVID Investigators.: Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19. Chest 160(3): 929-943, Sep 2021.

back to top
Last updated: 08/05/2022
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania. Site best viewed with a supported browser.
SOM Home International Programs Penn Alumni Clinical Trials Centers and Institutes Departments Faculty Research Education Administration